

Marketplace

DRUG NAME	Ruconest (C1 esterase inhibitor (recombinant))

Hereditary Angioedema (HAE)

initial



Dosage allowed/Quantity limit:

If all the above requirements are met, the medication will be approved for 6 months.

reauthorization

If all the above requirements are met, the medication will be approved for an additional 12 months.



CareSource considers Ruconest (C1 esterase inhibitor (recombinant)) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.